Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis

被引:84
作者
Rahnemai-Azar, Amir A. [1 ]
Weisbrod, Allison [2 ]
Dillhoff, Mary [2 ]
Schmidt, Carl [2 ]
Pawlik, Timothy M. [2 ]
机构
[1] Univ Washington, Med Ctr, Dept Surg, Seattle, WA 98195 USA
[2] Ohio State Univ, Dept Surg, Wexner Med Ctr, 395 W 12th Ave,Suite 670, Columbus, OH 43210 USA
来源
SURGICAL ONCOLOGY-OXFORD | 2017年 / 26卷 / 02期
关键词
Biliary tract cancer; Biomarkers; Diagnosis; Intrahepatic cholangiocarcinoma; Molecular pathogenesis; Prognosis; PRIMARY SCLEROSING CHOLANGITIS; BILIARY-TRACT CANCER; SERUM TUMOR-MARKERS; EPITHELIAL-MESENCHYMAL TRANSITION; COMPARATIVE GENOMIC HYBRIDIZATION; ISOCITRATE DEHYDROGENASE 1; MASS FORMING TYPE; TOTAL SIALIC-ACID; DETECTING CHOLANGIOCARCINOMA; HEPATOCELLULAR-CARCINOMA;
D O I
10.1016/j.suronc.2016.12.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor with increasing incidence worldwide. The outcome of patients with iCCA is dismal owing to tumor's aggressiveness, late diagnosis and lack of effective treatment options. Detection of the tumor at early stages may make surgical resection, as only potential curative treatment, more feasible. Unfortunately, despite recent developments in imaging modalities and laboratory tests, the diagnosis of iCCA remains challenging and patients often present in advanced stages when surgery cannot be offered. Moreover, accurate assessment of disease burden is critical to optimize management strategy, including the use of adjuvant therapies and clinical trials. Identifying iCCA specific diagnostic and prognostic biomarkers has been a focus of interest among many investigators with a progressive increase in data on iCCA related to advances in "omics" technologies. We herein summarize iCCA biomarkers and define the molecular mechanisms underlying iCCA carcinogenesis, as well as highlight potential diagnostic and prognostic application of molecular biomarkers. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:125 / 137
页数:13
相关论文
共 150 条
[41]   Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach [J].
Janvilisri, Tavan ;
Leelawat, Kawin ;
Roytrakul, Sittiruk ;
Paemanee, Atchara ;
Tohtong, Rutaiwan .
DISEASE MARKERS, 2015, 2015
[42]   Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level [J].
Kashihara, T ;
Ohki, A ;
Kobayashi, T ;
Sato, T ;
Nishizawa, H ;
Ogawa, K ;
Tako, H ;
Kawakami, F ;
Tsuji, M ;
Tamaoka, K .
JOURNAL OF GASTROENTEROLOGY, 1998, 33 (03) :447-453
[43]   Proteomic analysis reveals important role of 14-3-3σ in anoikis resistance of cholangiocarcinoma cells [J].
Khongmanee, Amnart ;
Lirdprapamongkol, Kriengsak ;
Tit-oon, Phanthakarn ;
Chokchaichamnankit, Daranee ;
Svasti, Jisnuson ;
Srisomsap, Chantragan .
PROTEOMICS, 2013, 13 (21) :3157-3166
[44]   Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma [J].
Kipp, Benjamin R. ;
Voss, Jesse S. ;
Kerr, Sarah E. ;
Fritcher, Emily G. Barr ;
Graham, Rondell P. ;
Zhang, Lizhi ;
Highsmith, W. Edward ;
Zhang, Jun ;
Roberts, Lewis R. ;
Gores, Gregory J. ;
Halling, Kevin C. .
HUMAN PATHOLOGY, 2012, 43 (10) :1552-1558
[45]  
Kirimlioglu H, 2009, TURK J GASTROENTEROL, V20, P41
[46]   Tumor-suppressor p53: Implications for tumor development and prognosis [J].
Kirsch, DG ;
Kastan, MB .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :3158-3168
[47]   Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells [J].
Kobayashi, S ;
Werneburg, NW ;
Bronk, SF ;
Kaufmann, SH ;
Gores, GJ .
GASTROENTEROLOGY, 2005, 128 (07) :2054-2065
[48]   Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes [J].
Komuta, Mina ;
Govaere, Olivier ;
Vandecaveye, Vincent ;
Akiba, Jun ;
Van Steenbergen, Werner ;
Verslype, Chris ;
Laleman, Wim ;
Pirenne, Jacques ;
Aerts, Raymond ;
Yano, Hirohisa ;
Nevens, Frederik ;
Topal, Baki ;
Roskams, Tania .
HEPATOLOGY, 2012, 55 (06) :1876-1888
[49]  
Kongtawelert P, 2003, WORLD J GASTROENTERO, V9, P2178
[50]  
Koopmann J, 2004, NEW ENGL J MED, V350, P2623